Drugs / Ibogaine

Trials 4 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT05029401 Apr 2021 → Jan 2024 substance withdrawal syndrome atai Therapeutics, Inc. Completed No outcome recorded
Phase 23 trials
Phase 2 NCT06810765 Sep 2025 → Dec 2026 cognitive disorder, post-traumatic stress disorder, traumatic brain injury Johns Hopkins University Withdrawn No outcome recorded
Phase 2 NCT03380728 Oct 2022 → Oct 2024 alcohol dependence University of Sao Paulo Completed No outcome recorded
Phase 2 NCT04003948 Oct 2020 → Apr 2024 opiate dependence International Center for Ethnobotanical Education, Research, and Service Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Ibogaine ClinicalTrials.gov intervention name — accepted as the source's own label NCT04003948
1

NCT06810765

Known as 10-methoxyibogamine ChEMBL registry synonym — accepted as the source's own label CHEMBL222287
Known as 12-methoxyibogamine ChEMBL registry synonym — accepted as the source's own label CHEMBL222287
Known as DMX-1002 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05029401
Known as Ibogaine Hydrochloride ClinicalTrials.gov intervention name — accepted as the source's own label NCT03380728
Known as Ibogamine, 12-methoxy- ChEMBL registry synonym — accepted as the source's own label CHEMBL222287
Known as NSC-249764 ChEMBL registry synonym — accepted as the source's own label CHEMBL222287
Modality Traditional medicine (herbal / TCM) “Ibogaine is an alkaloid present in the bush Tabernanthe iboga (iboga), a plant from Central Africa traditionally used in countries such as Gabon and Cameroon.” NCT03380728
Route Oral “receive oral doses of 20 to 400 mg of ibogaine” NCT03380728